Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
AI Drug Discovery: Texas A&M AI Tool Accelerates Tuberculosis Research
Texas A&M researchers develop CAGE-Fusion, an advanced AI model designed to filter false compounds and streamline tuberculosis drug discovery pipeline.
Bayer's Kerendia Wins NICE Recommendation for Heart Failure Treatment
UK health watchdog NICE recommends Bayer's Kerendia (finerenone) for NHS patients with chronic heart failure, expanding access to 280,000 people.
Taylor Farms Lettuce Recall: FDA Identifies Cause of Cyclospora Outbreak
FDA identifies Taylor Farms iceberg lettuce as the source of a Cyclospora outbreak affecting Taco Bell and Walmart across multiple US states. Read more.
Von Willebrand Disease Treatment: Hemab Reports HMB-002 Clinical Trial Data
Hemab Therapeutics shares promising Phase I/II clinical trial data for subcutaneous HMB-002, demonstrating reduced bleeding in Von Willebrand Disease.
Preclinical Alzheimer's Disease Risk: New Dual Biomarker Tracking Strategy
A new dual-biomarker strategy combining plasma p-Tau 217 and PET scans accurately tracks cognitive decline and neurodegeneration in Alzheimer's disease.
Targeted Cancer Therapy: Veraxa and Ardigen Partner for AI Drug Discovery
Veraxa Biotech and Ardigen launch an AI drug discovery collaboration to develop dual-target bispecific T-cell engagers for advanced cancer therapies.
AI Drug Discovery: Drug Farm Secures $55M Series D for Clinical Trials
Drug Farm closes a $55M Series D funding round to advance AI-driven clinical trials for ROSAH syndrome, Hepatitis B, and targeted metabolic therapies.
Malaria Drug Resistance: Artemisinin Treatments at Risk in East Africa
Artemisinin resistance is rising across East Africa, threatening front-line malaria treatments. Learn how mutating parasites impact global public health.
FDA Clears Gain Therapeutics to Launch Global Parkinson's Phase 2 Trial
Gain Therapeutics received FDA IND clearance to launch a multi-continent Phase 2 clinical trial of GT-02287, an oral small molecule for Parkinson's.
MIRA Pharmaceuticals Reports Promising SKNY-1 Data for Obesity Tracking
MIRA Pharmaceuticals shared new preclinical data for SKNY-1, an oral candidate demonstrating strong brain penetration and once-daily dosing potential.
UCLA Wins $7.49M CIRM Grant to Advance Novel Multiple Sclerosis Therapy
A UCLA research team led by Dr. Lili Yang secured a $7.49M CIRM grant to transition an engineered NKT cell-based immunotherapy for MS into clinical trials.
Breakthrough HIV Vaccine Candidate Shows Major Promise in Primate Study
An experimental HIV vaccine from LJI and Scripps Research successfully generated broadly neutralizing antibodies in primates, marking a historic milestone.
1
2
3
4
5
6
